ADVENTRX to Present at BIO CEO on February 14
February 03 2006 - 2:00PM
PR Newswire (US)
SAN DIEGO, Feb. 3 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX) announced today that Evan M.
Levine, president and CEO, will present a development update for
the Company's lead oncology drug, CoFactor(TM), and give a
corporate update at the 8th Annual BIO CEO & Investor
Conference on February 14 at 2 pm Eastern Time. BIO CEO takes place
in New York City at The Waldorf Astoria Hotel, February 14-15,
2006. The BIO CEO conference is hosted by the Biotechnology
Industry Organization (BIO), an organization focused exclusively on
biotechnology. Attendees will include institutional investors,
industry analysts, venture capitalists, investment bankers and
other industry experts. Additional conference details and online
registration are available at http://www.bio.org/. About CoFactor
CoFactor (ANX-510) is a folate-based biomodulator drug being
developed to enhance the activity and reduce associated toxicity of
the widely used cancer chemotherapeutic agent 5-fluorouracil
(5-FU). CoFactor creates more stable binding of the active form of
5-FU to the target enzyme, thymidylate synthase (TS), improving
5-FU performance. The Company reported Phase II results from an
independent radiological assessment that found an overall clinical
benefit of 85% and objective response of 35% in metastatic
colorectal cancer patients treated with CoFactor and 5-FU. The
Company also reported longer than expected time to tumor
progression (TTP), with no drug-related grade 3 or grade 4
gastrointestinal or hematological toxicities. CoFactor is also
being tested in a Phase IIb randomized controlled clinical trial to
evaluate CoFactor use with 5-FU as a first line treatment for
metastatic colorectal cancer. The Company has received clearance
under a special protocol assessment from the US Food and Drug
Administration (FDA) to begin a CoFactor Phase III pivotal clinical
trial for metastatic colorectal cancer, which is currently planned
to begin patient dosing in Q1 2006. About ADVENTRX ADVENTRX
Pharmaceuticals is a biopharmaceutical research and development
company focused on introducing new technologies for anticancer and
antiviral treatments that surpass the performance and safety of
existing drugs, by addressing significant problems such as drug
metabolism, toxicity, bioavailability and resistance. More
information can be found on the Company's Web site at
http://www.adventrx.com/. Forward-Looking Statement This press
release contains forward-looking statements, within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995, regarding ADVENTRX. Such statements are made
based on management's current expectations and beliefs. Actual
results may vary from those currently anticipated based upon a
number of factors, including uncertainties inherent in the drug
development process, the timing and success of clinical trials, the
validity of research results, and the receipt of necessary
approvals from the FDA and other regulatory agencies. For a
discussion of such risks and uncertainties, which could cause
actual results to differ from those contained in the
forward-looking statements regarding ADVENTRX, see the section
titled "Risk Factors" in ADVENTRX's last quarterly report on Form
10-Q, as well as other reports that ADVENTRX files from time to
time with the Securities and Exchange Commission. All
forward-looking statements regarding ADVENTRX are qualified in
their entirety by this cautionary statement. ADVENTRX undertakes no
obligation to release publicly any revisions, which may be made to
reflect events or circumstances after the date hereof. DATASOURCE:
ADVENTRX Pharmaceuticals, Inc. CONTACT: Andrea Lynn of ADVENTRX
Pharmaceuticals, Inc., +1-858-552-0866 Web site:
http://www.adventrx.com/ http://www.bio.org/ Company News On-Call:
http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024